Feedback
Settings

Settings

Goto Application

4,518 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 452
1.WO/2021/226278AN ULTRASENSITIVE RAPID AND PORTABLE CASE13D-BASED DIAGNOSTIC ASSAY
WO - 11.11.2021
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
 Appl.No PCT/US2021/030953 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor AKBARI, Omar
Provided herein is a viral RNA detection system, utilizing the RNA-targeting properties of the optimized Casl3d enzyme, CasRx, to detect SARS-CoV-2 RNA, e.g., synthetic SARS- CoV-2 RNA. The system detects novel target sequences conserved within the actively evolving genome, to provide a panel of diagnostic target sites least likely to result in false negatives due to genomic variation. Successful detection of viral RNA through both a fluorescence-based readout assay as well as a rapid paper dipstick lateral flow assay requiring no specialized laboratory equipment was shown. Low viral titers can be detected within minutes following only minutes of sample processing.
2.11208660Coronavirus iRNA compositions and methods of use thereof
US - 28.12.2021
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
 Appl.No 17321561 Applicant Alnylam Pharmaceuticals, Inc. Inventor Akin Akinc

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.

3.3901260CORONAVIRUS VACCINE
EP - 27.10.2021
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 21168938 Applicant BIONTECH RNA PHARMACEUTICALS GMBH Inventor SAHIN UGUR
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
4.WO/2022/140845NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID-19
WO - 07.07.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/CA2021/051873 Applicant VAL-CHUM, LIMITED PARTNERSHIP Inventor STAMATATOS, Leonidas
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
5.20230219993Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
US - 13.07.2023
Int.Class C07H 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
7Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
06Heterocyclic radicals
 Appl.No 17996430 Applicant SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Inventor Yuanchao Xie

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

6.WO/2023/128874NUCLEIC ACID SPONGES COMPRISING SEVERAL STEM-LOOP STRUCTURES IN ONE MOLECULE
WO - 06.07.2023
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/SG2022/050939 Applicant NATIONAL UNIVERSITY OF SINGAPORE Inventor LAVENNIAH, Annadoray
The disclosure herein relates to engineered nucleic acids, so-called nucleic acid sponges. These engineered nucleic acids comprise a plurality, preferably 2-6, stem-loop structures whereby each loop binds to an individually selected target. The nucleic acid may be adapted to bind to RNA molecules such as microRNA and by doing so can affect RNA post transcriptional modification and RNA translation. Kits, pharmaceutical compositions, and the engineered nucleic acids for use in methods of treatment are also disclosed.
7.WO/2025/137446SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF
WO - 26.06.2025
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
 Appl.No PCT/US2024/061278 Applicant GILEAD SCIENCES, INC. Inventor KOCEVSKA, Stefani
The disclosure provides solid forms of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.
8.WO/2025/000059COMPOUNDS AND USES THEREFOR
WO - 02.01.2025
Int.Class C07H 19/056
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
056Triazole or tetrazole radicals
 Appl.No PCT/AU2024/050715 Applicant GLYCOSYNNOVATIONS PTY LTD Inventor PAYNE, Alan David
Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).
9.WO/2021/173713HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19
WO - 02.09.2021
Int.Class A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
 Appl.No PCT/US2021/019468 Applicant ATEA PHARMACEUTICALS, INC. Inventor SOMMADOSSI, Jean-pierre
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
10.WO/2021/213500COMPOUNDS AND PHARMACEUTICAL USES THEREOF
WO - 28.10.2021
Int.Class C07C 69/88
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
69Esters of carboxylic acids; Esters of carbonic or haloformic acids
76Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
84of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
88with esterified carboxyl groups
 Appl.No PCT/CN2021/089301 Applicant SYNEURX INTERNATIONAL (TAIWAN) CORP. Inventor TSAI, Guochuan Emil
A compound of Formula (I) : (I) or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC=OR6, (C=O) R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).
# -